Malaria is caused by parasites of the genus Plasmodium, which is transmitted to humans through the bite of infected mosquitoes. Plasmodium falciparum, the deadliest of the malaria species, has a highly complex life cycle controlled by precise gene regulation. Understanding these regulatory processes is crucial to specifically combat the pathogen at different stages of development.

 Our new study reveals how regulatory proteins modulate genome-wide epigenetic mechanisms to control the precise timing of gene expression in the parasite. We show that the chromatin remodeler PfSnf2L is an essential regulator of “just-in-time” regulation of stage specifically expressed genes. The unique sequence and functional properties of PfSnf2L led to the identification of a highly specific inhibitor that only kills Plasmodium falciparum. A multidisciplinary approach, involving an innovative and unique screening platform for PfSnf2L inhibitors, genetic manipulation of malaria parasites and cutting-edge “OMICs” was used to uncover the role of PfSnf2L. This inhibitor represents a new class of antimalarials, potentially targeting all life cycle stages. 

 The new findings not only advance basic research but could also offer practical applications. Malaria remains one of the greatest global health threats. In 2022, there were an estimated 247 million infections and over 600,000 deaths, mostly in sub-Saharan Africa. Innovative solutions such as targeting developmental regulation are therefore urgently needed to offer new treatment options.

 The study was carried out by an interdisciplinary, multinational team led by Prof. Gernot Längst (University of Regensburg, Germany) and Prof. Markus Meissner (Ludwig-Maximilians University, Munich, Germany) involving researchers from The University of Zürich (Switzerland), The Pennsylvania State University (USA) and the University of Glasgow (UK).